Nue Life Publishes First Peer-Reviewed Study in Frontiers in Psychiatry

FEATURED
October 5, 2022

Nue Life

Nue Life
1 MIN READ

We’re thrilled to announce that our first peer-reviewed study is now published in Frontiers in Psychiatry: Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.

Frontiers in Psychiatry is one of the most-cited medical journals in mental health. The study was conducted with 664 of our patients, the second largest data set of any at-home sublingual ketamine treatment protocol.

The study analyzed the impact of our treatment protocol on patients with treatment-resistant depression and anxiety. It showed that after as few as three doses of ketamine therapy, nearly 50% of patients with moderate to severe depression saw a clinical response defined as a 50% reduction in their baseline PHQ-9 and GAD-7 scores (the standardized clinical measures of depression and anxiety, respectively). The clinical response rate improved to over 60% in patients who completed six doses.

The study was led by Nue Life’s Chief Medical Officer, Kazi Hassan, MD. Additional authors are William M. Struthers, PhD; Patrick Davis, MD, PhD; and Aditya Sankarabhotla, Nue Life’s VP of AI & Technology.

Read the full study here.

Join the Beckley Academy
Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Have you made up your mind to change your mind?

Need further advice?

Speak with our Welcome team.

Get Started
Begin your journey with us.
Sign up to the Nue Life newsletter.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
© 2024 NueCo Holdings, P.B.C. All Rights Reserved Reserved

NueCo Holdings, P.B.C. is a technology platform that provides services to affiliated independently owned and operated medical practices, and does not own, direct, or control the medical professionals providing the standard of care to their patients.
The Instagram logo.The Facebook logoThe Twitter, or X, logoThe LinkedIn logo
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.